¼¼°èÀÇ CAR T ¼¼Æ÷Ä¡·á ½ÃÀå : Ç¥Àû Ç׿øº°, Ä¡·á ¿ëµµº°, Áö¿ªº°
CAR T Cell Therapy Market, By Targeted Antigen, By Therapeutic Application, and By Region
»óǰÄÚµå : 1789415
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,330,000
Unprintable PDF & Excel (Single User License)
US $ 7,000 £Ü 9,846,000
PDF & Excel (Multi User License - Up to 7 Users)
US $ 10,000 £Ü 14,067,000
PDF & Excel (Corporate User License)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

CAR T ¼¼Æ÷Ä¡·á ½ÃÀåÀº 2025³â¿¡´Â 39¾ï 9,000¸¸ ´Þ·¯, 2032³â¿¡´Â 150¾ï 6,000¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2032³â CAGRÀº 20.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 39¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â 20.90% 2032³â ±Ý¾× ¿¹Ãø 150¾ï 6,000¸¸ ´Þ·¯

Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) T¼¼Æ÷ Ä¡·á´Â ¸é¿ª T¼¼Æ÷¸¦ ÀÌ¿ëÇØ ¾ÏÀ» ÆÄ±«ÇÏ´Â ¸é¿ªÄ¡·áÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. CAR T¼¼Æ÷ Ä¡·á´Â T¼¼Æ÷ÀÇ À¯ÀüÀÚ º¯ÇüÀ» ¼ö¹ÝÇϱ⠶§¹®¿¡ ¼¼Æ÷ ±â¹Ý À¯ÀüÀÚ Ä¡·á¶ó°íµµ ºÒ¸³´Ï´Ù. Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR)-T ¼¼Æ÷ Ä¡·á´Â ¹éÇ÷±¸ ºÐ¼â¹ýÀ̶ó´Â ÀýÂ÷·Î ÀÎü¿¡¼­ T ¼¼Æ÷¸¦ ÃßÃâÇÕ´Ï´Ù. ÀÌÈÄ T¼¼Æ÷¿¡ ƯÁ¤ Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) À¯ÀüÀÚ¸¦ Ãß°¡ÇÏ¿© º¯Çü½ÃŰ¹Ç·Î CAR T¼¼Æ÷¶ó°í ÇÕ´Ï´Ù. º¯ÇüµÈ ÈÄ ¼¼Æ÷´Â °è¼Ó Áõ½ÄÇÏ¿© ÀÎü¿¡ ÁÖÀԵ˴ϴÙ. ´Ù¾çÇÑ À¯ÇüÀÇ CAR T ¼¼Æ÷ Ä¡·á´Â ƯÁ¤ À¯ÇüÀÇ ¾Ï°ú ½Î¿ì±â À§ÇØ ¸¸µé¾îÁý´Ï´Ù. CAR-T ¼¼Æ÷´Â ȯÀÚº°·Î ¸ÂÃãÈ­µÇ¾î Ç÷¾×¿¡ ÁÖÀԵ˴ϴÙ. CAR T ¼¼Æ÷ Ä¡·á´Â ¾Ï°ú ½Î¿ì±â À§ÇÑ »õ·Î¿î À¯ÀüÀÚ Ä¡·á¹ýÀ¸·Î »ç¿ëµË´Ï´Ù. ƯÁ¤ ¾Ï¿¡ ´ëÇÑ ´Ù¾çÇÑ CAR-T ¼¼Æ÷ Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ¿¬±¸Çϱâ À§ÇØ ´Ù¾çÇÑ ÀÓ»ó ¹× ÀüÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)ÀÇ ±³À° Ä·ÆäÀÎ µî ¿©·¯ Á¤ºÎ¿¡¼­ ¾Ï¿¡ ´ëÇÑ ÀνÄÀ» È®»êÇϱâ À§ÇÑ Ä·ÆäÀÎÀ» ÁøÇàÇÏ´Â µî ´Ù¾çÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Á¦Ç° ½ÂÀΰú °°Àº ½ÃÀå ³» ÁÖ¿ä ±â¾÷µéÀÇ À¯±âÀû Àü·« äÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 5¿ù, ¼¼°è ÇコÄÉ¾î ±â¾÷ Áß ÇϳªÀÎ Novartis AG´Â Àç¹ß¼º ¶Ç´Â ³­Ä¡¼º ¿©Æ÷¼º ¸²ÇÁÁ¾ ¼ºÀΠȯÀÚ Ä¡·á¿¡ ´ëÇÑ Kymriah(tisagenlecleucel) CAR-T ¼¼Æ÷ Ä¡·áÁ¦¸¦ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. À̹ø ½ÂÀÎÀº ÀÓ»ó 2»ó ½ÃÇèÀ» ÅëÇØ 68%ÀÇ È¯ÀÚ¿¡¼­ ¾ç¼º¹ÝÀÀÀ» º¸ÀÎ Á¡À» ³ôÀÌ Æò°¡¹Þ¾Æ ÀÌ·ïÁ³½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ CAR-T ¼¼Æ÷ Ä¡·á ½ÃÀå, Ç¥Àû Ç׿øº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ CAR-T ¼¼Æ÷ Ä¡·á ½ÃÀå, Ä¡·á ¿ëµµº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ CAR-T ¼¼Æ÷ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦7Àå °æÀï ±¸µµ

Á¦8Àå ¼½¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Car T Cell Therapy Market is estimated to be valued at USD 3.99 Bn in 2025 and is expected to reach USD 15.06 Bn by 2032, growing at a compound annual growth rate (CAGR) of 20.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 3.99 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 20.90% 2032 Value Projection: USD 15.06 Bn

Chimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy which uses immune T cells to destroy cancer. CAR T cell therapy is also called as cell based gene therapy, as it involves gene altering in T cells. For chimeric antigen receptor (CAR)-T cell therapy, T cells are extracted from human body using a procedure called leukapheresis. Then after extraction, T cells are altered by adding the gene for the specific chimeric antigen receptor (CAR) and hence they are called as CAR T cells. After the alteration, the cells are kept to grow and then are infused into human body. Different type of CAR T cell therapy are made to fight specific type of cancer. CAR- T cells are customized for different patients and then infused in blood. CAR T cells therapy is used as a novel gene therapy to fight cancer. Different clinical and preclinical studies are going on to study the safety and efficacy of various CAR-T cell therapies for specific cancer. Moreover, several governments are taking initiatives such as campaigns to spread the awareness of cancer for example educational campaign by Centers for Disease Control and Prevention (CDC).

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product approval is expected to drive market growth over the forecast period. For instance, in May 2022, Novartis AG., one of the global healthcare company, received the U.S. Food and Drug Administration approval for Kymriah (tisagenlecleucel) CAR-T cell therapy for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on phase II clinical trial, evaluated with 68% of positive response from the patients.

Key features of the study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global CAR T Cell Therapy Market, By Targeted Antigen, 2020 - 2032, (USD Bn)

5. Global CAR T Cell Therapy Market, By Therapeutic Application, 2020 - 2032, (USD Bn)

6. Global CAR T Cell Therapy Market, By Region, 2020 - 2032, (USD Bn)

7. Competitive Landscape

8. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â